Biotech By Damian Garde and Adam Feuerstein Biogen CEO: Company was ‘wrong’ about initial Aduhelm price, ‘courageous’ to lower it
Biotech By Adam Feuerstein FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T treatment
Biotech By Matthew Herper and Megan Molteni Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions
Biotech By Matthew Herper and Megan Molteni Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
Biotech By Angus Chen A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
Health Tech By Mohana Ravindranath Telehealth companies are testing the waters with taking on more risk
Biotech By Adam Feuerstein Sarepta’s Duchenne gene therapy improves muscle function but debate lingers